NorthWest Biotherapeutics Inc (NWBO)

[Chiugray]

Doc Logic, Absolutely. I think the “improved Direct” will blow people’s shorts off. The Phase 1 trial used a very conservative treatment regimen, as it was a novel tech:
- Patients had multiple inoperable tumors, but only 1 tumor was injected with Direct
- Only 6 injections (3 in first 2 wks and 3 at month 2, 4, and 8)

In the Phase 2 trials, they plan to:
- Inject multiple inoperable tumors at each treatment visit, not just one.
- Provide more frequent injections
- Provide a larger total number of injections

https://nwbio.com/nw-bio-announces-data-date-dcvax-direct-phase-trial/

https://nwbio.com/dcvax-direct-trial-update-indicates-further-positive-responses-3-case-studies-show-no-live-tumor-cells-in-injected-tumors/

Because the
- number of Direct doses are not limited (leukapheresis is patient’s blood only)
- as opposed to DCVax-L’s which is limited (by the available tumor resection)
- a very large number of doses can be made in one manufacturing run
- allowing for flexible dosing over extended periods
- allows for a recurring treatment, a potential recurring revenue model